JP5869219B2 - 治療および美容適用のためのエリスロポイエチンおよびフィブロネクチン組成物 - Google Patents

治療および美容適用のためのエリスロポイエチンおよびフィブロネクチン組成物 Download PDF

Info

Publication number
JP5869219B2
JP5869219B2 JP2010520684A JP2010520684A JP5869219B2 JP 5869219 B2 JP5869219 B2 JP 5869219B2 JP 2010520684 A JP2010520684 A JP 2010520684A JP 2010520684 A JP2010520684 A JP 2010520684A JP 5869219 B2 JP5869219 B2 JP 5869219B2
Authority
JP
Japan
Prior art keywords
epo
wound
erythropoietin
fibronectin
tissue
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2010520684A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010536745A (ja
JP2010536745A5 (enExample
Inventor
サヘル ハメド，
サヘル ハメド，
Original Assignee
レメドー バイオメッド リミテッド
レメドー バイオメッド リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by レメドー バイオメッド リミテッド, レメドー バイオメッド リミテッド filed Critical レメドー バイオメッド リミテッド
Publication of JP2010536745A publication Critical patent/JP2010536745A/ja
Publication of JP2010536745A5 publication Critical patent/JP2010536745A5/ja
Application granted granted Critical
Publication of JP5869219B2 publication Critical patent/JP5869219B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/04—Chelating agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nutrition Science (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)
JP2010520684A 2007-08-16 2008-08-13 治療および美容適用のためのエリスロポイエチンおよびフィブロネクチン組成物 Active JP5869219B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US93549707P 2007-08-16 2007-08-16
US60/935,497 2007-08-16
US6431108P 2008-02-27 2008-02-27
US61/064,311 2008-02-27
PCT/IL2008/001119 WO2009022338A2 (en) 2007-08-16 2008-08-13 Erythropoietin and fibronectin compositions for therapeutic and cosmetic applications

Publications (3)

Publication Number Publication Date
JP2010536745A JP2010536745A (ja) 2010-12-02
JP2010536745A5 JP2010536745A5 (enExample) 2011-09-29
JP5869219B2 true JP5869219B2 (ja) 2016-02-24

Family

ID=40351263

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010520684A Active JP5869219B2 (ja) 2007-08-16 2008-08-13 治療および美容適用のためのエリスロポイエチンおよびフィブロネクチン組成物

Country Status (5)

Country Link
US (7) US20110123481A1 (enExample)
EP (1) EP2192907B1 (enExample)
JP (1) JP5869219B2 (enExample)
PL (1) PL2192907T3 (enExample)
WO (1) WO2009022338A2 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5564735B2 (ja) * 2009-07-31 2014-08-06 国立大学法人 熊本大学 アクアポリン３の発現調節剤
JP5823986B2 (ja) * 2010-02-23 2015-11-25 セバナ メディカル リミテッド 脂肪移植物の生存を増大させるための方法及び組成物
WO2014160496A1 (en) * 2013-03-13 2014-10-02 Stemetrix, Inc. Skin compositions and uses
US20160058910A1 (en) * 2013-05-07 2016-03-03 Natiional University Corporation Tokyo Medical And Dental University Method for preparing particulate decellularized tissue
US11213569B2 (en) 2015-09-04 2022-01-04 Remedor Biomed Ltd. Topical erythropoietin formulations and methods for improving wound healing with and cosmetic use of the formulations
WO2017104725A1 (ja) * 2015-12-16 2017-06-22 第一三共株式会社 創傷治療剤
CN109072271A (zh) 2016-01-15 2018-12-21 汉堡大学 用于制备鼠李糖基化类黄酮的方法
JP2019508383A (ja) 2016-01-15 2019-03-28 ウニベルジテート ハンブルグＵｎｉｖｅｒｓｉｔａｅｔ Ｈａｍｂｕｒｇ Ｏ−ラムノシル残基を有するフラボノイド型化合物
JP2019522652A (ja) * 2016-06-21 2019-08-15 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Ｂｒａｆ阻害剤を用いる創傷治癒
AU2017357374B2 (en) 2016-11-10 2023-05-18 Asc Regenity Ltd. Cosmetic formulations for topical applications containing erythropoietin-derived molecules
JP7605576B2 (ja) * 2018-07-25 2024-12-24 ポーラ化成工業株式会社 皮膚老化改善剤のスクリーニング方法
JP2020070270A (ja) * 2018-11-01 2020-05-07 御木本製薬株式会社 フィブロネクチン遺伝子発現促進剤
CN116531306A (zh) * 2023-02-27 2023-08-04 珠海盈盛联科生物科技有限公司 含重组人纤连蛋白具有修复功效组合物、制备方法及应用

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3755560A (en) 1971-06-30 1973-08-28 Dow Chemical Co Nongreasy cosmetic lotions
DE2437090A1 (de) 1974-08-01 1976-02-19 Hoechst Ag Reinigungsmittel
US4421769A (en) 1981-09-29 1983-12-20 The Procter & Gamble Company Skin conditioning composition
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US4929442A (en) * 1986-09-26 1990-05-29 Exovir, Inc. Compositions suitable for human topical application including a growth factor and/or related materials
US5124155A (en) 1988-06-21 1992-06-23 Chiron Ophthalmics, Inc. Fibronectin wound-healing dressings
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5264214A (en) 1988-11-21 1993-11-23 Collagen Corporation Composition for bone repair
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US5073372A (en) 1990-11-30 1991-12-17 Richardson-Vicks, Inc. Leave-on facial emulsion compositions
US5073371A (en) 1990-11-30 1991-12-17 Richardson-Vicks, Inc. Leave-on facial emulsion compositions
US5564345A (en) * 1993-05-11 1996-10-15 Park Ohio Industries Inc. Stackable table, table assembly, and tray and table combination
EP0673384A4 (en) * 1992-12-10 1996-10-09 Univ Minnesota POLYPEPTIDES USEFUL IN TREATING INFLAMMABLE DISEASES.
GB9315810D0 (en) * 1993-07-30 1993-09-15 Univ London Stabilised materials
US7112320B1 (en) * 1995-06-07 2006-09-26 Andre Beaulieu Solid wound healing formulations containing fibronectin
US6458889B1 (en) * 1995-12-18 2002-10-01 Cohesion Technologies, Inc. Compositions and systems for forming crosslinked biomaterials and associated methods of preparation and use
US6007802A (en) 1996-03-27 1999-12-28 The Procter & Gamble Co. Conditioning shampoo composition
AU744809B2 (en) * 1997-03-11 2002-03-07 Pola Chemical Industries Inc. Method for evaluating skin conditioning agents and process for producing external skin preparations
CA2232855C (en) * 1997-04-10 2007-10-09 Roche Consumer Health (Worldwide) Sa Pharmaceutical formulation
AU1905799A (en) * 1997-12-22 1999-07-12 Human Genome Sciences, Inc. Keratinocyte growth factor-2 formulations
US6194378B1 (en) * 1998-02-18 2001-02-27 The Research Foundation Of State University Of New York Fibronectin peptides-based extracellular matrix for wound healing
GB9804720D0 (en) 1998-03-05 1998-04-29 Unilever Plc Shampoo compositions
JP2003513682A (ja) 1998-07-24 2003-04-15 ファーマカル、バイオテクノロジーズ、インコーポレーテッド 骨組織復元システムおよび方法
US20020006418A1 (en) * 1998-10-13 2002-01-17 John Kung Composition to enhance permeation of topical skin agents
US20070129282A1 (en) * 1998-11-24 2007-06-07 Ahlem Clarence N Pharmaceutical treatments and compositions
US20030072737A1 (en) 2000-12-29 2003-04-17 Michael Brines Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs
US6960173B2 (en) 2001-01-30 2005-11-01 Eilaz Babaev Ultrasound wound treatment method and device using standing waves
US6585963B1 (en) * 2001-02-15 2003-07-01 Watson Pharmaceuticals, Inc. Nail compositions and methods of administering same
US6913762B2 (en) 2001-04-25 2005-07-05 Mayo Foundation For Medical Education And Research Stent having non-woven framework containing cells
US20030147825A1 (en) * 2001-06-08 2003-08-07 Chiarelli Joseph A. Personal care compostions containing inverse emulsion polymers
US20030068297A1 (en) * 2001-08-18 2003-04-10 Deepak Jain Composition and methods for skin rejuvenation and repair
US20040265268A1 (en) 2001-08-18 2004-12-30 Deepak Jain Compositions and methods for skin rejuvenation and repair
US7651684B2 (en) 2001-12-07 2010-01-26 Cytori Therapeutics, Inc. Methods of using adipose tissue-derived cells in augmenting autologous fat transfer
WO2003072748A2 (en) 2002-02-22 2003-09-04 University Of Washington Bioengineered tissue substitutes
EP1557175A4 (en) 2002-06-06 2009-12-09 Chugai Pharmaceutical Co Ltd MEANS FOR THE TREATMENT OF BONE MATERIAL CHANGES
EP1517988B1 (de) 2002-06-20 2013-05-08 Augustinus Bader Verwendung von Erythropoietin zur Geweberegeneration in vivo
DE10234192B4 (de) 2002-07-26 2009-11-26 Epoplus Gmbh Co.Kg Verwendung von Erythropoetin
DE10303584A1 (de) 2003-01-30 2004-08-12 Stauss, Robert, Dr. Verwendung von Erythropoietin (EPO) als ein Beschichtungsmaterial auf medizinischen Implantaten
NZ542501A (en) 2003-02-24 2009-09-25 Marinepolymer Tech Inc Compositions comprising chitin or chitosan and use thereof
US7459152B2 (en) 2003-04-23 2008-12-02 Rush University Medical Center Erythropoietin administration to improve graft survival
WO2005037304A1 (en) * 2003-10-17 2005-04-28 Crucell Holland B.V. Treatment and prevention of decubitus
CA2536041A1 (en) 2003-11-10 2005-05-26 Angiotech International Ag Medical implants and fibrosis-inducing agents
EP1550715A1 (de) 2003-12-30 2005-07-06 Bionethos Holding Gmbh Verfahren zur Regenation von Gewebe
RU2542391C2 (ru) 2003-12-30 2015-02-20 Аугустинус БАДЕР Способ регенерации ткани
US20050187158A1 (en) * 2004-01-22 2005-08-25 Ranby Mats G. Pharmaceutical composition
DE102004063927A1 (de) * 2004-01-23 2005-12-15 Epoplus Gmbh Co.Kg Einsatz von niedrig dosiertem Erythropoietin zur Stimulation endothelialer Vorläuferzellen sowie zur Organregeneration und Progressionsverlangsamung von Endorganschäden
US7473678B2 (en) 2004-10-14 2009-01-06 Biomimetic Therapeutics, Inc. Platelet-derived growth factor compositions and methods of use thereof
WO2006105665A1 (en) * 2005-04-06 2006-10-12 Bioartificial Gel Technologies Inc. Hydrogel composition for modulation of topical inflammatory response
DE102005019712A1 (de) 2005-04-28 2006-11-09 Bayer Healthcare Ag Dipyridyl-dihydropyrazolone und ihre Verwendung
CA2608021A1 (en) * 2005-05-10 2006-11-16 Dermipsor Ltd. Compositions and methods for skin care
US7312198B2 (en) * 2005-07-12 2007-12-25 Essential Skincare, Llc Protein compositions for promoting wound healing and skin regeneration
WO2007055760A2 (en) 2005-10-31 2007-05-18 Essential Skincare, Llc Protein composition for promoting wound healing and skin regeneration
EP1976972B1 (en) 2006-01-24 2014-03-12 Brown University Cell aggregation and encapsulation device and method
DK2656832T3 (en) * 2006-05-11 2019-04-08 Regenics As Compositions for use in wound healing
CN101553206B (zh) * 2006-11-09 2012-11-21 爱尔康研究有限公司 用于药物递送的水不溶性聚合物基质
US7717855B2 (en) * 2006-12-06 2010-05-18 The Hospital For Sick Children System for performing remote ischemic preconditioning
CA2685534A1 (en) * 2007-04-30 2008-11-06 Living Proof, Inc. Use of matrix metalloproteinase inhibitors in skin care
JP2010530882A (ja) 2007-06-19 2010-09-16 バクスター・インターナショナル・インコーポレイテッド Ｐｄｇｆの制御放出のためのフィブリンゲルおよびその使用
EP2018835B1 (de) * 2007-07-09 2014-03-05 Augustinus Bader Wirkstoff abgebendes Pflaster
US20090045968A1 (en) 2007-08-16 2009-02-19 Optimal Innovations Inc. Utility Outlets Capable of Presenting Images
EP2222327B1 (de) 2007-12-28 2017-02-15 Augustinus Bader Topische anwendung und formulierung von erythropoietin für die wundheilung der haut
WO2009093240A2 (en) 2008-01-24 2009-07-30 Ademex Ltd. Erythropoietin and fibronectin compositions for bone regeneration

Also Published As

Publication number Publication date
US20160030525A1 (en) 2016-02-04
WO2009022338A2 (en) 2009-02-19
US20110123481A1 (en) 2011-05-26
WO2009022338A3 (en) 2010-03-04
US20220000987A1 (en) 2022-01-06
US20140154205A1 (en) 2014-06-05
US10792338B2 (en) 2020-10-06
EP2192907A2 (en) 2010-06-09
US20190192637A1 (en) 2019-06-27
US20170056480A1 (en) 2017-03-02
JP2010536745A (ja) 2010-12-02
EP2192907A4 (en) 2011-07-06
EP2192907B1 (en) 2018-04-18
US20190117740A1 (en) 2019-04-25
PL2192907T3 (pl) 2018-10-31

Similar Documents

Publication Publication Date Title
JP5869219B2 (ja) 治療および美容適用のためのエリスロポイエチンおよびフィブロネクチン組成物
JP7495150B2 (ja) 局所エリスロポエチン製剤および前記製剤を用いて創傷治癒を改善するための方法および前記製剤の美容用途
US10960012B2 (en) Bismuth-thiols as antiseptics for biomedical uses, including treatment of bacterial biofilms and other uses
AU2018204190A1 (en) Bismuth-thiols as antiseptics for biomedical uses, including treatment of bacterial biofilms and other uses
CA2788669A1 (en) Bismuth-thiols as antiseptics for biomedical uses, including treatment of bacterial biofilms and other uses
US20200390841A1 (en) Compositions and methods for treating wounds
CA3168280A1 (en) Chronic wound healing composition and application thereof
ES2438640B1 (es) Composición para la regeneración y reparación de la piel
US11633425B2 (en) Anti-glycation compositions
RU2777367C2 (ru) Местные эритропоэтиновые составы, способы улучшения заживления раны и косметическое применение составов
KR20230136597A (ko) 상처 치료를 위한 조성물들 및 방법들

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110810

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110810

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130517

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130718

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130725

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20140131

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20140530

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140530

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20140530

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20140711

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20140912

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20141201

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20141204

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20150406

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151002

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20151005

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20160107

R150 Certificate of patent or registration of utility model

Ref document number: 5869219

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250